Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone

Clinica Chimica Acta

Volumn 400, Issue 1-2, 2009, Pages 48-55

  Ruaño, Gualberto ^a   Bernene, James ^b   Windemuth, Andreas ^a   Bower, Bruce ^a   Wencker, Detlef ^c   Seip, Richard L ^a   Kocherla, Mohan ^a   Holford, Theodore R ^d   Petit, William A ^b   Hanks, Steven ^b  

^a Genomas Inc   (United States)

^b NEW BRITAIN GENERAL HOSPITAL   (United States)

^c HARTFORD HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADORA1; Adverse effects; Genetics; Physiogenomics; Thiazolidinediones

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADIPONECTIN RECEPTOR 2; BETA2 GLYCOPROTEIN 1; BIGUANIDE; CASEIN KINASE I; DIURETIC AGENT; GROWTH HORMONE RELEASING FACTOR; INCRETIN; INSULIN; LIGAND; NEUROPEPTIDE Y; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PIOGLITAZONE; PYRUVATE KINASE; ROSIGLITAZONE; SULFONYLUREA; UNCOUPLING PROTEIN 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL PERMEABILITY; BODY MASS; BODY WEIGHT; COMORBIDITY; DRUG MEGADOSE; EDEMA; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN; LOW DRUG DOSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSIOGENOMICS; PRIORITY JOURNAL; PROTEIN MOTIF; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DRUG TOXICITY; EDEMA; FEMALE; GENOMICS; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 57949115681     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.10.009     Document Type: Article

References (74)

1. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
2. Krentz A.J. Comparative safety of newer oral antidiabetic drugs. Expert Opin. Drug Safety 5 (2006) 827-834
3. FDA ALERT: Information for Healthcare Professionals. Pioglitazone HCl (marketed as Actos, Actoplus Met, and Duetact). Food and Drug Administration 8-14-2007. Accessed on 8-30-2007.
4. ACTOS Label. Takeda Pharmaceuticals America, Inc. 2007. Deerfield, IL, Takeda Pharmaceuticals America, Inc. 9-19-2007.
5. AVANDIA Label. GlaxoSmithKline. 11-14-2007. Research Triangle Park, NC, GlaxoSmithKline. 11-19-2007.
6. Sotiropoulos K.B., Clermont A., Yasuda Y., et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J. 20 (2006) 1203-1205
7. Mittra S., Sangle G., Tandon R., et al. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?. Br. J. Pharmacol. 150 (2007) 480-487
8. Sanchez-Hidalgo M., Martin A.R., Villegas I., and de la Lastra C.A. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur. J. Pharmacol. 562 (2007) 247-258
9. Berger J.P., Petro A.E., Macnaul K.L., et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 17 (2003) 662-676
10. Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
11. Balkrishnan R., Rajagopalan R., Shenolikar R.A., Camacho F.T., Whitmire J.T., and Anderson R.T. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. Curr. Med. Res. Opin. 20 (2004) 1633-1640
12. Pfutzner A., Schneider C.A., and Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev. Cardiovasc. Ther. 4 (2006) 445-459
13. Richter B., Bandeira-Echtler E., Bergerhoff K., Clar C., and Ebrahim S.H. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. (2006) CD006060
14. Richter B., Bandeira-Echtler E., Bergerhoff K., Clar C., and Ebrahim S. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. (2007) CD006063
15. Bosello O., and Zamboni M. Visceral obesity and metabolic syndrome. Obes. Rev. 1 (2000) 47-56
16. Cheung K.J., Tzameli I., Pissios P., et al. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab. 5 (2007) 115-128
17. Yuan S.Y., Breslin J.W., Perrin R., et al. Microvascular permeability in diabetes and insulin resistance. Microcirculation 14 (2007) 363-373
18. Bando Y., Ushiogi Y., Okafuji K., Toya D., Tanaka N., and Fujisawa M. Troglitazone combination therapy in obese type 2 diabetic patients poorly controlled with alpha-glucosidase inhibitors. J. Int. Med. Res. 27 (1999) 53-64
19. Sotiropoulos K.B., Clermont A., Yasuda Y., et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J. 20 (2006) 1203-1205
20. Walker A.B., Naderali E.K., Chattington P.D., Buckingham R.E., and Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47 (1998) 810-814
21. Saltelli A., Chan K., and Scott E.M. Sensitivity analysis (2000), John Wiley and Sons, Chichester
22. Ruano G., Windemuth A., and Holford T. Physiogenomics: integrating systems engineering and nanotechnology for personalized medicine. In: Bronzino J.D. (Ed). The biomedical engineering handbook. 3rd ed (2005), CRC Press, querry here 28-1-28-9
23. Twigger S.N., Pasko D., Nie J., et al. Tools and strategies for physiological genomics: the rat genome database. Physiol. Genomics 23 (2005) 246-256
24. Malek R.L., Wang H.Y., Kwitek A.E., et al. Physiogenomic resources for rat models of heart, lung and blood disorders. Nat. Genet. 38 (2006) 234-239
25. Lee N.H. Physiogenomic strategies and resources to associate genes with rat models of heart, lung and blood disorders. Exp. Physiol. 92 (2007) 992-1002
26. Holford T.R., Windemuth A., and Ruano G. Designing physiogenomic studies. Pharmacogenomics 7 (2006) 157-158
27. Ruano G., Thompson P.D., Windemuth A., et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 6 (2005) 865-872
28. Ruano G., Thompson P.D., Windemuth A., et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 36 (2007) 329-335
29. Ruano G., Goethe J.W., Caley C., et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry 12 (2007) 474-482
30. Ruano G., Windemuth A., Kocherla M., et al. Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction. Nutr. Metab. (Lond) 3 (2006) 20
31. Seip R.L., Volek J.S., Windemuth A., et al. Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat. Nutr. Metab. (Lond) 5 (2008) 4
32. Ruano G., Seip R.L., Windemuth A., et al. Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training. Atherosclerosis 185 (2006) 65-69
33. Oliphant A., Barker D.L., Stuelpnagel J.R., and Chee M.S. BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques Suppl:56-1 (2002)
34. Fan J.B., Oliphant A., Shen R., et al. Highly parallel SNP genotyping. Cold Spring Harbor Symp. Quant. Biol. 68 (2003) 69-78
35. G. Ruano, Physiogenomic method for predicting clinical outcomes of treatments in patients. (20060278241). 12-14-2006.
36. Reiner A., Yekutiele D., and Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19 (2003) 368-375
37. Brown C.C., and Fears T.R. Exact significance levels for multiple binomial testing with application to carcinogenicity screens. Biometrics 37 (1981) 763-774
38. Heyse J., and Rom D. Adjusting for multiplicity of statistical tests in the analysis of carcinogenicity studies. Biom. J. 30 (1988) 883-896
39. Cleveland W.S., and Devlin S.J. Locally weighted regression: an approach to regression analysis by local fitting. J. Am. Stat. Assoc. 83 (1988) 596-610
40. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
41. National Institutes of Health (NIH) and National Heart, Lung and Blood Institute NHLBI. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. vol. 1. 1998. Washington, D.C., Health and Human Services, Public Health Service.
42. Olivier M. From SNPs to function: the effect of sequence variation on gene expression. Focus on "a survey of genetic and epigenetic variation affecting human gene expression". Physiol. Genomics 16 (2004) 182-183
43. Pastinen T., Sladek R., Gurd S., et al. A survey of genetic and epigenetic variation affecting human gene expression. Physiol. Genomics 16 (2004) 184-193
44. Tsukada S., Tanaka Y., Maegawa H., Kashiwagi A., Kawamori R., and Maeda S. Intronic polymorphisms within TFAP2B regulate transcriptional activity and affect adipocytokine gene expression in differentiated adipocytes. Mol. Endocrinol. 20 (2006) 1104-1111
45. Tokuhiro S., Yamada R., Chang X., et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat. Genet. 35 (2003) 341-348
46. LaNoue K.F., and Martin L.F. Abnormal A1 adenosine receptor function in genetic obesity. FASEB J. 8 (1994) 72-80
47. Challis R.A., Budohoski L., McManus B., and Newsholme E.A. Effects of an adenosine-receptor antagonist on insulin-resistance in soleus muscle from obese Zucker rats. Biochem. J. 221 (1984) 915-917
48. Challiss R.A., Richards S.J., and Budohoski L. Characterization of the adenosine receptor modulating insulin action in rat skeletal muscle. Eur. J. Pharmacol. 226 (1992) 121-128
49. Londos C., Honnor R.C., and Dhillon G.S. cAMP-dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase regulators. J. Biol. Chem. 260 (1985) 15139-15145
50. Green A. Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist. J. Biol. Chem. 262 (1987) 15702-15707
51. Kaartinen J.M., Hreniuk S.P., Martin L.F., Ranta S., LaNoue K.F., and Ohisalo J.J. Attenuated adenosine-sensitivity and decreased adenosine-receptor number in adipocyte plasma membranes in human obesity. Biochem. J. 279 Pt 1 (1991) 17-22
52. Crist G.H., Xu B., LaNoue K.F., and Lang C.H. Tissue-specific effects of in vivo adenosine receptor blockade on glucose uptake in Zucker rats. FASEB J. 12 (1998) 1301-1308
53. Dong Q., Ginsberg H.N., and Erlanger B.F. Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity-related insulin resistance. Diabetes Obes. Metab. 3 (2001) 360-366
54. Ashizawa K., Willingham M.C., Liang C.M., and Cheng S.Y. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J. Biol. Chem. 266 (1991) 16842-16846
55. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
56. Damcott C.M., Ott S.H., Pollin T.I., et al. Genetic variation in adiponectin receptor 1 and adiponectin receptor 2 is associated with type 2 diabetes in the Old Order Amish. Diabetes 54 (2005) 2245-2250
57. Bouchard C., Perusse L., Chagnon Y.C., Warden C., and Ricquier D. Linkage between markers in the vicinity of the uncoupling protein 2 gene and resting metabolic rate in humans. Hum. Mol. Genet. 6 (1997) 1887-1889
58. Fisler J.S., and Warden C.H. Uncoupling proteins, dietary fat and the metabolic syndrome. Nutr. Metab. (Lond) 3 (2006) 38
59. Nan Y.S., Feng G.G., Hotta Y., et al. Neuropeptide Y enhances permeability across a rat aortic endothelial cell monolayer. Am. J. Physiol, Heart Circ. Physiol. 286 (2004) H1027-H1033
60. Hamdy O., Nishiwaki K., Yajima M., et al. Presence and quantification of neuropeptide Y in pulmonary edema fluids in rats. Exp. Lung Res. 26 (2000) 137-147
61. Basterra J., Dilly P.N., Perez M., and Chumbley C.C. Vasoactive intestinal polypeptide and neuropeptide-Y, as possible mediators in laryngeal oedema. An immunofluorescence study. Acta Otorhinolaryngol. Belg. 43 (1989) 99-104
62. Dimitrijevic M., Stanojevic S., Vujic V., et al. Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). J. Neuroimmunol. 129 (2002) 35-42
63. Stamatovic S.M., Dimitrijevic O.B., Keep R.F., and Andjelkovic A.V. Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J. Biol. Chem. 281 (2006) 8379-8388
64. Kuma Y., Campbell D.G., and Cuenda A. Identification of glycogen synthase as a new substrate for stress-activated protein kinase 2b/p38beta. Biochem. J 379 (2004) 133-139
65. Picton C., Aitken A., Bilham T., and Cohen P. Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Organisation of the seven sites in the polypeptide chain. Eur. J. Biochem. 124 (1982) 37-45
66. Juhaszova M., Zorov D.B., Kim S.H., et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 113 (2004) 1535-1549
67. Mehta J.L., and Li D.Y. Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem. Biophys. Res. Commun. 248 (1998) 511-514
68. Hu C., Dandapat A., and Mehta J.L. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension 50 (2007) 952-957
69. Katz S.D. Blood volume assessment in the diagnosis and treatment of chronic heart failure. Am. J. Med. Sci. 334 (2007) 47-52
70. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108 (2003) 2941-2948
71. Das E.N., and King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 55 (2007) 498-510
72. Hong G., Lockhart A., Davis B., et al. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J. 17 (2003) 1966-1968
73. Eap C.B., Bochud M., Elston R.C., et al. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 49 (2007) 1007-1014
74. Pascual-Le Tallec L., Demange C., and Lombes M. Human mineralocorticoid receptor A and B protein forms produced by alternative translation sites display different transcriptional activities. Eur. J. Endocrinol. 150 (2004) 585-590